Ni
Non vérifié

Nimbus Therapeutics, LLC

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté
10/11/2026
Industrie
Science
Médecine - Divers
Biotechnologie
Santé Publique
Santé
Industrie pharmaceutique
Nimbus Therapeutics Announces First-in-Human Dosing of NDI-225673, an Investigational Selective SIK2 Inhibitor for Immune-Mediated Inflammatory Diseases
1.00
05/11/2026
Événements
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Santé
Technique
Nimbus Therapeutics to Present New Preclinical Data on Selective SIK2 Inhibition in Rheumatoid Arthritis at ACR Convergence 2026
1.00
05/11/2026
Événements
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Santé
Technique
Nimbus Therapeutics to Present New Preclinical Data on Selective SIK2 Inhibition in Rheumatoid Arthritis at ACR Convergence 2026
1.00
13/10/2026
Technique
Science
Biotechnologie
Santé
Industrie pharmaceutique
Oncologie
Marché du travail
Nimbus Therapeutics Strengthens Leadership Team to Support Next Phase of Growth
1.00
16/04/2026
Événements
Biotechnologie
Industrie pharmaceutique
Santé
Médecine - Divers
Nimbus Therapeutics Presents New Mechanistic Data Highlighting Differentiated Biology of Selective SIK2 Inhibitors at IMMUNOLOGY2026™
1.00
06/01/2026
Marché du travail
Industrie
Science
Fitness/Bien-être
Médecine - Divers
Biotechnologie
Santé Publique
Santé
Industrie pharmaceutique
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment
1.00
19/12/2025
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
1.00
25/04/2025
Industrie
Oncologie
Santé
Santé Publique
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
1.00
07/03/2025
Marché du travail
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
Nimbus Therapeutics Appoints Abbas Kazimi as Chief Executive Officer
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0